Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director Mark Steven Davis sold 6,100 shares of the firm's stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $5.62, for a total value of $34,282.00. Following the completion of the transaction, the director owned 100,565 shares of the company's stock, valued at approximately $565,175.30. This represents a 5.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Myriad Genetics Price Performance
Shares of NASDAQ MYGN traded up $0.01 on Thursday, hitting $5.54. The company's stock had a trading volume of 1,168,021 shares, compared to its average volume of 1,880,884. The stock has a 50 day moving average of $4.89 and a 200-day moving average of $4.62. The company has a market capitalization of $531.41 million, a price-to-earnings ratio of -4.07 and a beta of 1.62. Myriad Genetics, Inc. has a 12-month low of $2.74 and a 12-month high of $8.09. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.98 and a quick ratio of 1.77.
Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative net margin of 16.07% and a negative return on equity of 19.87%. The business had revenue of $202.70 million during the quarter, compared to the consensus estimate of $191.33 million. As a group, research analysts predict that Myriad Genetics, Inc. will post -1.02 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on MYGN shares. Wall Street Zen raised Myriad Genetics from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. Stephens raised their price target on shares of Myriad Genetics from $3.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 12th. Zacks Research raised shares of Myriad Genetics from a "strong sell" rating to a "hold" rating in a research report on Thursday, October 15th. Wells Fargo & Company set a $4.50 price target on shares of Myriad Genetics in a research note on Tuesday, October 20th. Finally, Weiss Ratings cut shares of Myriad Genetics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, October 27th. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $5.98.
Check Out Our Latest Research Report on MYGN
Hedge Funds Weigh In On Myriad Genetics
Several hedge funds and other institutional investors have recently modified their holdings of MYGN. Allworth Financial LP bought a new stake in Myriad Genetics during the 2nd quarter valued at $25,000. Integrated Wealth Concepts LLC bought a new stake in shares of Myriad Genetics during the second quarter valued at about $54,000. Pinnacle Associates Ltd. bought a new stake in shares of Myriad Genetics during the third quarter valued at about $44,000. Hsbc Holdings PLC acquired a new stake in Myriad Genetics in the second quarter worth about $61,000. Finally, E Fund Management Co. Ltd. acquired a new stake in Myriad Genetics in the second quarter worth about $67,000. Institutional investors and hedge funds own 99.02% of the company's stock.
About Myriad Genetics
(
Get Free Report)
Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests to help inform healthcare decisions. Its offerings include tests for hereditary cancer risk, tumor biology and prognosis, reproductive health, and how patients may respond to certain medications. Its products include MyRisk, which assesses inherited cancer risk; GeneSight, a pharmacogenomic test intended to help guide psychiatric medication decisions; and Prolaris, which helps assess the aggressiveness of prostate cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.